Armistice Capital: Shaping the Future of Biotech Investments
Armistice Capital has emerged as a pivotal player in the dynamic realm of biotech investments, wielding significant influence over industry trends and funding patterns. Under the guidance of Steven Boyd, the firm’s founder and managing partner, Armistice Capital has demonstrated a knack for identifying promising opportunities in a sector known for its volatility and high-stakes […]